Clinical Outcome between Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndrome and Diabetes
Table 2
Clinical outcomes in ACS patients with diabetes.
Total ()
Ticagrelor plus aspirin ()
Clopidogrel plus aspirin ()
value
Efficacy outcome
Composite endpoint
41 (15.4%)
19 (14.3%)
22 (16.5%)
0.610
Nonfatal MI
0 (0.0%)
0 (0.0%)
0 (0.0%)
—
Target vessel revascularization
15 (5.6%)
5 (3.8%)
10 (7.5%)
0.184
Rehospitalization
17 (6.4%)
9 (6.8%)
8 (6.0%)
0.802
Ischemic stroke
3 (1.1%)
1 (0.8%)
2 (1.5%)
1.000
Death from any cause
6 (2.3%)
4 (3.0%)
2 (1.5%)
0.680
BARC type
BARC 1~5
53 (19.9%)
32 (24.1%)
21 (15.8%)
0.091
BARC 1
38 (14.3%)
21 (15.8%)
17 (12.8%)
0.483
BARC 2
10 (3.8%)
8 (6.0%)
2 (1.5%)
0.053
BARC 3
4 (1.5%)
2 (1.5%)
2 (1.5%)
1.000
BARC 4
0 (3.5%)
0 (0.0%)
0 (0.0%)
—
BARC 5
1 (0.4%)
1 (0.8%)
0 (0.0%)
1.000
Data were expressed as (%) and median (IQR). IQR: interquartile range; value, Pearson chi-square test, continuity correction test, or Fisher’s exact test; composite endpoints included MI, revascularization, rehospitalization for angina, stroke, and death from any cause; BARC: Bleeding Academic Research Consortium definition for bleeding; MI: myocardial infarction.
